Instructions for Encephabol (Pyritinol) 50 tablets 100 mg
Features
Minimum age from. 1 year
Method of use Oral
Pack quantity 50 pcs
Minimum storage temperature allowed, °C 2 °C
Maximum storage temperature allowed, °C 25 °C
Storage Conditions In a sunproof room
Release form Pill
Country of manufacture Austria
Active substance Pyritinol
Scope Neurology
Pharmacological group N06BX02 Pyritinol
Registered as Medicinal agent
Release form
tab, envelope, 100 mg: 50 pcs
Description:
Tablets covered with a yellow shell, shiny; round, double-convex; two layers are visible on the cross section.
1 tab.
Pyritinol dihydrochloride monohydrate 100 mg
Auxiliary substances:
sodium carmellose - 1.6 mg,
magnesium stearate - 3.2 mg,
silicon dioxide colloidal - 4.8 mg,
sodium carboxymethyl starch - 6.4 mg,
lactose monohydrate - 19.8 mg,
cellulose powder - 24.2 mg.
Shell Composition:
the dye quinoline yellow 70% - 30 μg,
mountain glycolic wax - 80 μg,
gelatin - 800 μg,
acacia gum - 1.7 mg,
wheat flour - 8.2 mg,
titanium dioxide - 9 mg,
kaolin - 14.2 mg,
talc - 14.3 mg,
sucrose - 121.69 mg.
10 pcs - blister packs (5) - cardboard packs.
ATC codes
N06BX02 Pyritinol
Clinical-pharmacological groups / Group affiliation
Nootropic preparation
Active substance
Pyritinol dihydrochloride monohydrate
Pharmacotherapy group
Nootropic agent
Storage Conditions:
The drug Encephabol should be stored in a place inaccessible to children at a temperature of 15-25 °C.
Best before date
Shelf life is 5 years.
Testimony Encephabol:
Symptomatic treatment of impaired brain function, with concomitant dementia,
namely degenerative dementia, dementia of vascular genesis or mixed forms of degenerative and vascular dementia in the presence of the following major syndromes:
a breakdown of memory, concentration, and thought;
other vascular syndromes of the brain in cerebrovascular diseases.
Supportive therapy for the effects of traumatic brain injury in the presence of the following main symptoms:
a violation of consciousness;
attention and concentration disturbance;
brain dysfunction.
Disorders of mental development in children and adolescents.
Method of use, course and dosage:
Adults: In 2 tablets 3 times/day (600 mg of Pyritinol dihydrochloride monohydrate per day).
Children from 7 years: 1 tablet 1-3 times/day (100 to 300 mg of Pyritinol dihydrochloride monohydrate per day, depending on indications).
The drug Encephabol should be taken during or after meals. For sleep disorders, the last daily dose should not be taken in the evening or at night.
The duration of treatment depends on the clinical picture of the disease. As a rule, therapeutic success is achieved after 3-4 weeks of treatment. The optimal effect usually occurs in 6-12 weeks. Treatment should be at least 8 weeks long and may be continued if necessary.
After 3 months, check for indications for further treatment.
Application for kidney disorders
The drug Encephabol is contraindicated in kidney diseases in the anamnesis.
Use in liver disorders
The preparation is contraindicated in cases of pronounced liver dysfunctions.
Terms of Sale
The drug Encephabol is prescription.
Nosology (ICD codes)
F01
Vascular dementia
F03
Dementia unspecified
F07
Personality and behavioural disorders caused by disease, damage or brain dysfunction
F79
Mental retardation unspecified
F80
Specific disorders of speech and language development
F81
Specific learning disabilities
F84
General disorders of psychological development
F89
Developmental disorder
I67.2
Cerebral atherosclerosis
I69
Effects of cerebrovascular disease
S06
Intracranial injury
T90
Effects of head injuries
Pharmacological effect:
Nootropic drug Encephabol.
Increases pathologically reduced metabolism in the tissues of the brain, which is due to increased glucose capture and utilization, increases the metabolism of nucleic acids and the release of acetylcholine in the synapses of nerve cells, improves cholinergic transmission in the nervous tissue. Pyritinol helps stabilize the structure of cell membranes of neurons and their function by inhibiting lysosomal enzymes, thesis preventing the formation of free radicals
